ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
13 announcements with these filters
Sotac Pharmaceuticals clarified that recent share price movements are entirely market-driven. The company confirmed it has disclosed all material information in compliance with SEBI regulations.
Sotac's EGM sought shareholder approval to raise authorised share capital from Rs.11.5 crore to Rs.15 crore. The video-conference meeting had one resolution.
Sotac Pharmaceuticals will hold an Extraordinary General Meeting on October 31, 2026, to seek shareholder approval for an increase in the company's authorised share capital.
Sotac Pharmaceuticals approved increasing its authorized share capital to Rs. 15 Crore. An Extra-Ordinary General Meeting will be convened to seek shareholder approval for this change.
Sotac Pharmaceuticals Limited has announced a record date of September 23, 2026, for the payment of a final dividend of Rs. 0.20 per share.
Sotac Pharmaceuticals Limited issued the notice for its 11th Annual General Meeting on September 30, 2026. Ordinary and special business will be transacted.
Sotac Pharmaceuticals' board approved the 11th AGM for September 30, 2026, and recommended a dividend of Rs. 0.20 per share.
Sotac Pharmaceuticals received a purchase order from Intas Pharmaceuticals Limited for finished pharmaceutical formulations. The order is valued at ₹0.98 Crore.
Sotac Pharmaceuticals recommended a final dividend of ₹0.20 per equity share for FY 2025-26. The distribution awaits shareholder approval at the upcoming AGM.
Sotac Pharmaceuticals Limited reported revenue from operations of ₹60.1 Cr (+27.6% YoY) and net profit of ₹3.3 Cr (-45.9% YoY) for H2 FY26.
Sotac Pharmaceuticals reported audited FY26 results and proposed a Rs. 0.20 per share dividend. Consolidated annual revenue reached ₹101.24 Crore with a net profit of ₹5.77 Crore.
Sotac Pharmaceuticals Limited submitted its annual SDD Compliance Certificate for the year ended March 31, 2026. The filing confirms regulatory compliance under PIT Regulations.
Sotac Pharmaceuticals scheduled a board meeting for May 26, 2026. The board will consider audited financial results and a final dividend for fiscal 2026.